Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Lisa Steinhelfer; Friederike Jungmann; Lukas Endrös; Patrick Wenzel; Bernhard Haller; Manuel Nickel; Eva Haneder; Fabian Geisler; Katharina Götze; Alexander von Werder; Matthias Eiber; Markus R. Makowski; Rickmer Braren; Fabian Lohöfer

doi:10.2967/jnumed.123.267098

Research ArticleBasic Science Investigation

Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina Götze, Alexander von Werder, Matthias Eiber, Markus R. Makowski, Rickmer Braren and Fabian Lohöfer

Journal of Nuclear Medicine August 2024, 65 (8) 1244-1249; DOI: https://doi.org/10.2967/jnumed.123.267098

Lisa Steinhelfer

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Friederike Jungmann

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lukas Endrös

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrick Wenzel

2Medical Clinic and Polyclinic II, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bernhard Haller

3Institute of AI and Informatics in Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Manuel Nickel

3Institute of AI and Informatics in Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Eva Haneder

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fabian Geisler

2Medical Clinic and Polyclinic II, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Katharina Götze

4Medical Clinic and Polyclinic III, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alexander von Werder

2Medical Clinic and Polyclinic II, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

5Department of Nuclear Medicine, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; and

6German Cancer Consortium, a Partnership Between DKFZ and School of Medicine, Technical University of Munich, Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Markus R. Makowski

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rickmer Braren

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

6German Cancer Consortium, a Partnership Between DKFZ and School of Medicine, Technical University of Munich, Munich, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fabian Lohöfer

1Department of Radiology, School of Medicine, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Individuals

Non-Member Login

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 8

August 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine Aug 2024, 65 (8) 1244-1249; DOI: 10.2967/jnumed.123.267098

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine Aug 2024, 65 (8) 1244-1249; DOI: 10.2967/jnumed.123.267098

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

PRRT
spleen volumetry
imaging-based biomarker
177Lu-DOTATATE
leukopenia

Main menu

User menu

Search

Spleen Volume Reduction Is a Reliable and Independent Biomarker for Long-Term Risk of Leukopenia Development in Peptide Receptor Radionuclide Therapy

Individuals

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords